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Abstract 
Human Papillomavirus(HPV) vaccine has been internationally recognised to decrease 
the prevalence of HPV related diseases. Introduced to New Zealand with a female focus 
in 2008, the researcher of this study wanted to explore the advantages and 
disadvantages of providing a funded vaccination programme to males aged between the 
ages of 9-20 years. 
Through the use of a systematic literature review, six articles were used for data 
extraction, synthesis and analysis to determine the advantages and disadvantages of 
introducing a funded vaccine for males. 
Four emerging results were determined through the use of data extraction, analysis and 
synthesis. These were then presented in a narrative form to establish both advantages 
and disadvantages of introducing a funded vaccine programme for males. 
With discussion focused on the main findings and how that could fit to a New Zealand 
immunisation programme. 
Good evidence was found to support that the HPV vaccme decreased HPV viruses 
(vaccinated types), however results also showed that extending vaccination to males could 
not, at this stage, be considered cost effective. Fmiher evidence regarding the health benefits 
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The following dissertation is an integrative literature review investigating the advantages and 
disadvantages of vaccinating males aged between nine to twenty years with the 
Human Papillomavirus (HPV) vaccine. The review was performed using a systematic 
approach utilising a framework provided by Joanna Briggs Institute (JBI). The topic is close 
to the author's interest having worked for over ten years in primary health care in rural 
Southland as an independent vaccinator and practice nurse. This interest has increased with 
the introduction of vaccination against HPV for New Zealand females aged between nine and 
twenty years. Of patiicular interest is the decision to restrict vaccination to females in 
New Zealand, when Australia's HPV vaccination programme includes males. On a personal 
note, the author has two sons adding to her professional interest in exploring the advantages 
and/or disadvantages to vaccinating boys. Recently after the introduction of the HPV 
vaccine for females the author attended a course leading to a certificate of proficiency in 
reproductive and sexual health, cementing her interest in the current regulations 
surrounding the HPV vaccine and its delivery to particular demographic groups. It is this 
history that has led her to complete her dissertation on the current topic. 
1 
2 Background 
This chapter will focus on the introduction of vaccination in New Zealand and the evolution 
of vaccination programmes within New Zealand. It will outline the introduction of the HPV 
vaccine to the New Zealand immunisation schedule and the development and rationale for its 
inclusion onto the schedule. Infonnation regarding the HPV disease itself and the advantages 
of vaccination will be considered with reference to other similar immunisation programmes 
worldwide. Vaccination with the HPV vaccine for males will be discussed using an evidence 
based practice approach, extending to universal vaccination and herd immunity. 
Vaccination within New Zealand has been unde1iaken for nearly a century and was first 
documented in 1926 with the introduction of vaccination for diphtheria at a small number of 
orphanages and schools at the request of local medical officers (MOH, 2011 ). The diphtheria 
vaccination programme was fmiher developed, and was first offered in 1941 to all children 
aged seven years, delivered through the Plunket Society and medical services. This was the 
initiation of a whole population vaccination programme in New Zealand and was motivated 
by recunent diphtheria epidemics. The period 1940-1948 saw the introduction of tetanus, 
pertussis and later the BCG vaccine, extended mainly to nurses as the recipients, with all 
vaccination being voluntary at the time (MOH, 2011). In 1961, New Zealand's first national 
immunisation policy was developed, and included diphtheria, tetanus and pe1iussis vaccines 
to be provided free of charge to children (MOH, 2011; Richardson, 2013). Since the initiation 
of New Zealand's National Immunisation Schedule (NIS), the programme now consists of 
over thirteen different vaccinations, some of which are combined into a single vaccination for 
ease of delivery. 
In 2004 the Ministry of Health introduced New Zealand's National Immunisation Register 
(NIR). It was initially implemented district by district and monitored the delivery of vaccines. 
It is now used to monitor vaccine coverage nationally. All individuals are registered with their 
own personal health index number, which is used to repo1i any infectious diseases to the 
Ministry of Health. The introduction of the NIR has been revolutionary in the monitoring of 
disease progression and vaccine coverage. As a result, the Ministry is now able to identify 
uptake rates and also detennine the efficacy of a vaccine that has been implemented (MOH, 
2011, as cited in Richardson, 2013). 
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New Zealand has a funded immunisation schedule, which allows access to vaccines for free 
for selected groups as detennined by need. In 2012, parliament passed legislation that allowed 
New Zealand's Pharmaceutical Management Agency (PHARMAC) to control the purchasing 
and management of all New Zealand's vaccines. The MOH, however, remains responsible for 
the National Immunisation Schedule (MOH, 2011). For a vaccine or phannaceutical to be 
placed on the New Zealand National Immunisation Schedule, Medsafe must first approve it 
for use, and then a submission must be presented before PHARMAC for consideration to be 
included as a funded vaccine. PHARMAC will then detennine a funding proposal with a 
supplier for the cost of a vaccine and then seek input from various health sources, including 
the Ministry of Health on need, capacity and possible implementation of the vaccine. Once a 
decision has been made to add a vaccine to the National Immunisation Schedule it then 
becomes each District Health Board's (DHB) responsibility to use their funding for vaccines, 
medicines and other health services implemented (MOH, 2011, as cited in Richardson, 2013). 
Once it is decided which vaccines are safe and to be funded these are added to what is known 
as the National Immunisation Schedule. The cun-ent immunisation schedule covers free 
childhood immunisations for diphtheria, tetanus, acellular pe1iussis, inactivated polio, 
haemophilus influenza type b, hepatitis B, 13-valent pneumococcal conjugate, rotavirus, 
measles, mumps and rubella until aged 11 years. HPV vaccine is offered for girls 12 years of 
age, through a series of tlu·ee vaccines. The schedule also offers funded vaccines for 
diphtheria and tetanus for adults at age 45years and 65 years. Influenza vaccine is offered for 
over 65 years and high risk groups that are identified by disease and health status. 
The selection of vaccines for the national schedule does cause some controversy, paiiicularly 
for the introduction of a new vaccine. This is mainly due to the debate from different 
specialities as to which diseases need to be decreased or are having the most impact on an 
already stretched healthcare system as detennined by different specialties. PHARMAC 
funding models are competitive in nature and this aids to the debate of which vaccines are a 
priority to include within an already full and stretched schedule. Evolution of the schedule is 
constant and parameters for inclusion continually change. Examples of these could be either 
rubella, HPV, or the push to have varicella included to the schedule, however many factors 
such as cost, implementation, efficacy and delivery of the vaccines must be considered 
(Richardson, 2013). 
The history of vaccines in New Zealand continues to evolve. A case in point would be the 
introduction of Rubella in 1970, which included all 4 year olds and a catch-up offered to 5 to 
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9 year olds through school. Due to poor uptake, it was re-structured within the schedule in 
1979 to include 11-year-old girls only, similarly in tenns of age to the current HPV vaccine. 
In 1990, a single composite vaccination was introduced to include rubella along with measles 
and mumps and was extended to all 12 to 15 month old children, with a booster vaccine 
recommended at four years of age (MOH, 2011). 
In 2008 the Human Papillomavirus (HPV) was introduced to New Zealand's immunisation 
schedule as a quadrivalent vaccine, and was extended to 12-year-old girls only, with a catch-
up schedule implemented to include all females born post 1990 (MOH, 2011). In 2013 this 
was extended to include males less than twenty-six years of age with a confinned diagnosis of 
HIV. A year later, this was also extended further to include females with a confamed 
diagnosis of HIV (MOH, 2014). 
In 2007 the New Zealand HPV Project was developed by a group of professionals dedicated 
to improving education and management ofHPV within New Zealand for both the public and 
health professionals. The project disseminated important infonnation about potential benefits 
of HPV vaccination (Gardasil TM) in preventing the spread of the HPV virus consequently 
avoiding genital manifestations of HPV in both females and males. HPV vaccination in 
females prevents genital waiis, cervical, vaginal and vulval pre-cancerous lesions, and their 
progression. If given before exposure to the virus, HPV vaccination in males offers an 
effective method of avoiding genital pre-cancerous lesions, anal cancer and other associated 
cancers in males, provided they were not previously exposed (New Zealand HPV project, 
2015). 
2.1 AETIOLOGY OF DISEASE 
The Human Papillomavirus (HPV) was discovered over a century ago and was first thought to 
be responsible for all types of human warts. However, it is now known to have over one 
hundred different serotypes and is responsible for multiple diseases and clinical 
manifestations (CDC, 2015). Three decades of research and investigation has led to the 
discovery that HPV is responsible for both cervical cancers and cancers of the anal, penile, 
head and neck regions (CDC, 2015). This discovery has resulted in the development of HPV 
vaccines and realisation of the need for more vaccine programmes for both genders 
worldwide. 
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Although one hundred different serotypes exist, they can be categorised into two different 
groups. First, mucosa/genital types of which there are over forty serotypes and second, 
non-mucosal/cutaneous types of which there are over sixty serotypes. The mucosal/genital 
types are known as high-risk types of HPV. It is these that can lead to changes ranging from 
low-grade dysplasia of the cervical cells, cancer precursors and ano-genital cancers, to genital 
warts and laryngeal papilloma's. Non-mucosal types are less serious and responsible for warts 
of the hands and feet (CDC, 2015; New Zealand HPV Project, 2015). Considering the 
multiple serotypes of HPV, it is possible for a person to contract more than one serotype. 
Each serotype is distinguished by a genetic sequence found via its protein LI on the outer 
capsid (CDC, 2015). 
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2.2 TRANSMISSION 
Transmission occurs, via direct contact when the virus infiltrates through the squamous 
epithelial layer of skin to reach the deeper basal epithelial cells. Once access is gained through 
small micro-abrasions the virus uses the skin's healing process to promote the attachment of 
virions to squamous epithelial cells (Immunisation Handbook, 2014). Disease progression 
occurs post initial infection, highlighting the imp01iance of vaccination pre-exposure to the 
HPVvirus. 
Considered as one of the most common sexually transmitted diseases in the world, much 
focus smTounds HPV being contracted sexually. However, skin on skin contact alone can be 
responsible for contraction of the disease (CDC, 2015; New Zealand HPV Project, 2015; 
Immunisation Advisory Centre, 2015). Condoms are widely promoted as the best protection 
against transmission, but protection is not guaranteed using condoms alone. 
Chances of contracting HPV are increased with unprotected sexual intercourse and multiple 
pminers. It is also widely known that gender, ethnicity or demographics appear to play no 
specific role in increase or reduction in contracting the disease. There is evidence to suggest 
that in individuals who have sexual intercourse with an HPV infected pminer, approximately 
two thirds of them will develop genital wmis (Arima et al., 2010). Many HPV infections 
typically clear spontaneously through cytotoxic lymphocytosis, a natural immunological 
response. However, the re-infection or persistent infection with high-risk HPV strains of the 
virus is considered a risk factor for the aforementioned cancers, with persistent infection 
leading to abnonnal precancerous cell changes, posing a risk for both females and males 
(CDC, 2015; National Screening Unit, 2015). Unfortunately, a high percentage of those who 
contract HPV will be asymptomatic and will have no clinical manifestation, which aids the 
spread of the disease, and is not a reflection of the destructive and devastating character of the 
virus or sequelae of infection that it may cause (CDC, 2015; Immunisation Advisory Centre, 
2015; New Zealand HPV project, 2015). 
Although HPV is thought to play a major part in the development of multiple diseases, 
environmental and social risk factors are also known to be contributors in the development of 
sequelae of HPV infection. Factors such as tobacco use, pregnancy, ultraviolet radiation, 
folate deficiency and immune suppression are thought to be contributors of disease 
progression (Medscape, 2015). 
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2.3 VACCINES AND VACCINATION 
Three HPV vaccines exist and these were developed usmg the HPV virus. HPV has 
microscopic capsid proteins, which interact with a6B4 integrin, an enzyme of wound repair, 
allowing for cell entry and replication. These microscopic capsid proteins are used to make 
the antigen for the HPV vaccines that have been developed. These inactivated vaccines are 
recommended for the prevention of several different types ofHPV (CDC, 2015). 
Of the two vaccines approved in New Zealand, Gardasil™ is promoted as it gives immunity 
to four (16, 18, 6, & 11) serotypes to prevent vulval, cervical and anal cancers. It is also 
promoted for the prevention of pre-cancerous lesions or abnonnality to these regions, to 
prevent genital waiis and specifically the high-risk serotypes of the HPV infection itself (Best 
Practice Advocacy Centre New Zealand(Bpac), 2012). The vaccine has proven safety, with 
data demonstrating that after five years and nearly 404,500 people vaccinated the chance of 
an adverse reaction is less than 0.01 %, indicating that the chance of a severe reaction is low 
(MOH, 2014). The publicly funded vaccine for girls is said to cost approximately $500 for 
three doses of Gardasil™ (New Zealand HPV Project, 2015). The cost of the alternative 
vaccine, Cervarix TM, is approximately $154 per dose with three doses equalling 
approximately $462 for a full three-dose course, however Cervarix TM only vaccinates against 
two serotypes 16 and 11 which give coverage to genital warts but not high risk serotypes that 
can lead to cancers (New Zealand HPV Project, 2015). 
A variety of treatments are available for genital waiis ranging from solutions for a person to 
apply to the genital area (for example, condyline™, Aldara™, and Trichloroacetic acid™), or 
either cryotherapy or laser removal which is performed by a health professional 
(New Zealand HPV Project, 2015). Treatment for genital waiis is invasive as the treatment 
must be applied to the genital region. There is also a financial cost which both males and 
females incur if they seek treatment through primary health care services. However treatment 
for some age groups is funded, an example of this is the under 25 year age group who are 
funded for free sexual health or contraceptive consultations at a District Health Board level, 
depending on that boards decisions regarding funding distribution (Wellsouth, 2015). Funded 
consults might also apply to people over 25 years of age, but this is need dependant. The 
treating nurse or doctor has to evaluate whether or not the individual fits the criteria for their 
District Health Board's funding. When available the funding can be claimed through general 
practices or sexual health clinics with the intention to increase accessibility towards better 
sexual health (Wellsouth, 2015). 
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As noted previously the New Zealand HPV programme was developed m 2008, with 
vaccination, first offered to women born in 1990 or later. 
The Ministry of Health at this time assessed overseas HPV programmes that were already 
being implemented and instigated its own HPV programme, which was adapted to suit 
New Zealand. These adaptations included only funding the HPV vaccine for girls instead of 
both genders, and, in most regions, offering a school based delivery system, which was 
thought to enable accesibility (New Zealand HPV Project, 2015). 
The scheduled vaccines are delivered to the majority of girls through a school-based 
programme. Although the vaccine is approved for use in females aged between 9 to 45 years 
and males between 9 to 15 years, government funding cun-ently only covers vaccination cost 
for girls aged nine to twenty years. Non-funded, but approved vaccines can be delivered in 
primary care practice with recommendation from a general practitioner (MOH, 2014; Best 
Practice Advocacy Centre New Zealand, 2012). 
2.4 EFFICACY AND EFFECTIVENESS 
A decrease in the contraction of HPV in women through vaccination could have an immense 
beneficial effect by reducing the rates of cervical cancer, other cancers and HPV related 
diseases (WHO, 2015). This could also have an impact on the male population by reducing 
HPV transmission and acquisition, even in the absence of male vaccination. 
Worldwide it is thought that 40 countries have implemented vaccination programmes for 
HPV (WHO, 2015). However, a number of countries also have baiTiers to the implementation 
of a robust HPV vaccine delivery system, especially in developing countries. A number of 
countries that are still in the early stages of implementing health initiatives such as de-
worming, visual screening, nutrition and other earlier initiatives would struggle with HPV 
implementation as these require amenities and skilled health workers that the other initiatives 
do not. For example, a cold chain accreditation is required to ensure the safe delivery of 
vaccines and appropriate storage of vaccines, making the implementation and storage of HPV 
vaccinations complicated for those developing countries (WHO, 2015). A number of 
countries fund HPV vaccination for women in the same age group as in New Zealand (WHO, 
2015). Many of these programmes are in the early years of implementation and no empirical 
data is yet available making it difficult to gauge the full effects of the programme and the full 
impact it will have on cancers, including cervical cancers. 
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There is increasing evidence of effectiveness of the cmTently implemented programmes 
(mainly for females), although longer tenn disease prevention is not yet demonstrable 
(Tabrizi et al., 2012) due to the time it takes to assess the disease progression to the cancerous 
stages. An assessment of Australia's national HPV vaccination programme reviewed the 
initial effect that the programme had on HPV infections in women who were attending 
Family Planning clinics (Tabrizi et al., 2012). The records of women between 18-24 years, 
before and after the commencement of the vaccination programme were reviewed. 
Inconsistencies in data collection were reduced through using the same clinics, age groups, 
strategies and collection methods. The findings noted that the frequency of HPV genotypes in 
the post vaccination group of women was 28% lower than the pre-vaccination group (Tabrizi 
et al., 2012). This study suggested that the vaccine, while in the earlier stages of initiation, is 
contributing to a decrease in the occmTence and spread of the HPV (Tabrizi et al., 2012). 
Early evidence from New Zealand also suggests effectiveness from the HPV vaccine despite 
being in the early stages of initiation. Between 2009 and 2012, the number of people 
presenting to sexual health clinics with genital wmis decreased by 32% post vaccination 
programme initiation (MOH, 2014). Family planning clinics also noted a decrease in genital 
wmi presentations by a massive 52%(Ministry of Health, 2014). The decrease was noted 
across all ethnicities and was predominantly in women from the 15- to 19-year-old age 
bracket, the group first offered the vaccination through the HPV vaccination programme. 
Although in its early stages of implementation, this data suggests the effectiveness that the 
HPV vaccination programme is already having for women in New Zealand (Immunisation 
Handbook, 2014). 
Some vaccinations have been found to have a decline in effect over time. For example, 
Diphtheria antitoxin levels decrease after the initial three doses given and have been shown to 
provide a waning immunity, causing careful consideration of long-tenn coverage 
(Immunisation Handbook, 2014). The New Zealand HPV vaccination programme has now 
been running for just over seven years and the results show no indication of declining 
immunity. However, it is possible that in the future a booster could be needed yet it will be a 
while longer before this is known (Immunisation Handbook, 2014). 
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2.5 COST EFFECTIVENESS 
As indicated above, cost effectiveness is an important consideration when introducing a new 
vaccine. After recognising that HPV is a universal disease that affects both men and women 
and can lead to further disease development for both a number of studies have attempted to 
evaluate the worth of including males in HPV vaccination programmes worldwide (CDC, 
2015; New Zealand HPV Project, 2015; WHO, 2015). Overall, the findings are controversial. 
A study canied out by Elbasha and Dasbach (2010) assessed the value of vaccinating males 
against HPV in America. In their study they evaluated the monetary w011h of vaccination 
versus the likely health impact of vaccination of the male population, in protecting against 
HPV types of cancer or genital warts. Figures from publicly available health data were 
applied to models that projected the cost of treatment for both genital warts and for cancers 
that might be contracted from HPV strains 6/11/16/18. These costs were then used as a 
comparison against the vaccination costs of the male population between ages 9 and 26 years. 
It was found that by vaccinating this demographic and age group, the health benefits to males 
were widespread and financially a viable option. It also looked at longevity and quality of life, 
concluding a considerable health and financial benefit to both (Elbasha & Dasbach, 2010). 
Chesson, Ekwueme, Saraiya, Dunne, & Markowitz (2011) also estimated cost-effectiveness 
for vaccinating the male population in America by using models that evaluate the reduction of 
economic and health burden that is related to HPV associated diseases. The study used a 
simplified model to establish the cost of the vaccine then the cost of acquiring, detecting, and 
treating HPV associated diseases. The authors concluded that it became economical to 
vaccinate against HPV for males only when the uptake of vaccination was low in females. 
Much discussion was provided on whether it would be better financially to achieve a higher 
uptake of female vaccination, which would also provide some protection for males through 
herd immunity. The authors dete1mined that if vaccination coverage for females were greater, 
it would reduce the overall problem of HPV over the entire population (Chesson, Ekwueme, 
Saraiya, Dunne, & Markowitz, 2011). 
A study perfonned by de Kok, Habbema, Rosmalen, and Ballegooijen (2011) clearly po11rays 
a financial and economic benefit for vaccinating against all HPV associated diseases. The 
authors studied the estimated potential of the maximum effect of HPV vaccination on non-
cervical HPV cancers. Using a mathematical equation they estimated the impact HPV 
vaccination could have on reducing cancers other than cervical. They focused instead on 
penile, oral cavity, oropharynx, anal, vaginal and vulval cancers. Using simulation that 
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related to these other cancers they took into account the life years earned, savings and cost 
effectiveness of the vaccine which lead to a 18% increase in savings, and made vaccination 
13% more cost effective. The authors concluded that if HPV vaccination was to completely 
prevent all of the non-cervical cancers caused by HPV, then there would be a substantial 
increase in the cost effectiveness of vaccinating not only the female population, but the male 
population too (de Kok, Habbema, Rosmalen, & Ballegooijen, 2011) 
.Estimating cost of vaccination versus the burden of disease triggered by HPV is hard to 
comprehend as a majority of studies have used frameworks to establish costs. The 
frameworks have been used to estimate the cost of vaccine versus the perceived cause of 
disease and its progression. However few studies have evidence based research, or if they do 
this is often based on early programme implementation and includes evaluation of genital 
waiis rather than HPV related cancers. This estimation and framework use creates room for 
debate with regard to the actual cost of HPV vaccination programmes and the savings that 
could transpire. However, the literature ce1iainly raises questions as to whether there could be 
health benefits for extending the vaccination programmes to include males. 
2.6 HERD IMMUNITY 
Immunity is considered to be the body's biological state where individuals are capable of 
defending themselves against a particular disease. This occurs through complex mechanisms 
that identify and remove an infection or disease from the body before it can become harmful 
(Immunisation Handbook, 2014). hnmunity can be acquired in three different fonns; active 
immunity, where an individual has acquired the disease themselves and the body has 
produced antibodies during the initial eradication of the disease and would recognise these 
should they acquire it again, or through vaccination where an individual is administered the 
disease antigen or a small amount of live vaccine, such as MMR, for the body to build its own 
antibodies to fight the disease. It can also be acquired passively which often occurs in utero 
or through the breast milk via the host, or by vaccination with serum that includes antibodies 
(hnmunisation Handbook, 2014). 
In addition to the immunity an individual can acquire, another type of immunity is known as 
herd immunity, which occurs when a high number of individuals have been administered a 
vaccine for disease protection, therefore lowering the incidence, creating a population-wide 
reduction of the disease and subsequently reducing the spread of the disease. When levels of a 
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disease are low it is said that people are protected by herd immunity, whereby most of the 
herd are immune and, therefore, the remainder of the herd's chances of meeting or being 
smrnunded by infected people is reduced (Immunisation Handbook, 2014). 
A lot of controversy surrounds the topic of herd immunity, with some research determining 
that herd immunity is as good as vaccination once disease prevalence is low and other 
research determining that people should be able to access health care themselves to ensure 
that they have direct immunity to the disease rather than relying on herd immunity from the 
greater community. 
The New Zealand Immunisation handbook (MOH, 2014) noted a decrease in the prevalence 
of HPV that has been seen in unvaccinated young men in Australia since the initiation of their 
National HPV vaccination programme which targets women and girls in the same age group 
similarly to New Zealand's HPV programme. Australian investigators have concluded that 
this reduction in the prevalence of HPV (vaccinated types) in unvaccinated heterosexual 
young men was linked to herd immunity (MOH, 2014). It was also noted in one Australian 
clinic that there was a viliual elimination of genital warts not only in young women but also 
in young heterosexual men at the same time, in the same age bracket. It also noted that there 
was no decrease in genital warts presentation in women over the vaccinated age bracket or 
amongst men who have sex with men demographic, further supporting the hypothesis this 
reduction was likely to be from vaccination (MOH, 2014). 
The New Zealand immunisation handbook also discusses the possibility of cross-protection 
that has been seen for non-vaccinated HPV types. Non-vaccinated HPV types are responsible 
for approximately one third of cervical cancers. There is said to be a small reduction in these 
cancers for the immunised groups (Immunisation Handbook, 2014). 
2.7 ISSUES OF TARGETED VACCINATION 
Cun-ently in New Zealand vaccination is funded for females between the ages of 9 to 20 
years. The omission of males brings to question the literature that has exposed HPV as a 
health issue for males as much as it is for females. Although the full effect of HPV and its 
relationship specifically with cancer is yet to be fully understood, there are notable links 
(hnmunisation Handbook, (2014). Literature also suggests that male vaccination is founded 
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on many assumptions or factors to debate whether it is a financially viable option for 
immunisation programmes (Cifu & Davis, 2014). Literature also shows that immunisation of 
females in New Zealand is likely to provide some herd immunity for males; this has yet to be 
verified or statistically validated (Immunisation handbook, (2014). It could be argued that by 
vaccinating boys and men, it will in fact offer some immunity to women and girls. 
Men are also responsible for transmitting the infection to women, therefore when immunising 
girls only, other demographics and genders are left unprotected, leaving girls only with 
ce1iainty of protection. This leaves a percentage of New Zealand's population unprotected 
(for example, men having sex with men), leaving them at a higher risk of contracting HPV. 
Today's youth are very transient in nature, this is supported by migration numbers from 
statistics New Zealand, with an increase of travellers in the year 2000 of 3,873,000 travellers 
venturing overseas to 4,554,600 in 2014, showing vast increase in travel (Statistics 
New Zealand, 2015). Such mobility should be considered when weighing up whether to offer 
immunisation to females alone. By offering males the vaccine we would also be providing a 
wider and more thorough base for herd immunity. 
Consideration of the international context is necessary, as over the last two decades travel has 
changed significantly with the introduction of more overseas flights at cheaper rates and an 
increase in tourism worldwide. As noted earlier, many countries are said to lack resources to 
offer immunisation for HPV thus providing a new dimension to analyse (WHO, 2015). 
For worldwide herd immunity to occur there would need to be a reasonable uptake of HPV 
vaccination at a global level. However with some countries lacking resources to implement 
HPV vaccination it is going to take time for all countries to establish these immunisation 
practices. For a country, such as New Zealand, the frequency of travel beyond the 
geographical border means that it will be difficult to establish herd immunity. In addition to 
the countries that simply cannot afford an HPV vaccination programme, uptake in the 
countries providing HPV vaccination isn't proven to be high. As a result, there remains a 
huge population that are potential carriers and from whom New Zealand males might contract 
HPV infection. Ministry of Health, (2014) suggests that over 70% uptake of the vaccine needs 
to be obtained to give good herd immunity against HPV and this target has yet to be reached 
in New Zealand. As HPV vaccination is funded for women, it appears that a case might also 
be made for it to be funded for boys or adolescent men, especially when these are both high-
risk groups for other sexually transmitted diseases. 
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Nyitray et al. (2011) sum up the status quo regarding inclusion of males in the vaccination 
programme by stating that vaccines can prevent infection and disease among both women and 
men, vaccine programmes have primarily targeted women, in part, due to a greater burden of 
disease among women, and also due to limited availability of HPV data for men (Nyitray et 
al., 2011). 
However significant data and literature exists that supports the recommendation of 
vaccination of males, but the progression of implementing this into existing immunisation 
programmes has been slow(NZ HPV Project, 2014; MOH, 2014; CDC, 2015) .. 
2.8 Current Regime 
New Zealand currently offers a funded HPV vaccine for girls from year 8-13. This is a series 
of three state funded injections delivered through either pmiicipating schools who are visited 
by their district health boards HPV team or through general practices. Other included 
individuals for a funded vaccine are individuals aged below 26 years of age with HIV 
infections or those immunocompromised. Transplant patients and men who have sex with 
men are also funded for a series of 3 HPV vaccines according to New Zealands immunisation 
schedule (MOH, 2014). 
2.9 UNIVERSAL VACCINATION OR OPTIONAL VACCINATION 
Vaccine coverage is a widely debated topic. The first question often asked is, how do we 
reach or meet our target population? Tabrizi et al. (2012) discussed the benefits of the 
implementation of the school-based delivery system in the Australian HPV vaccination 
programme. This programme has stated to have a 55% uptake of women emolling to have the 
vaccine. It was not compulsory to register whether or not you were participating, so it is 
thought that the uptake was actually higher than 55% (Tabrizi et al., 2012). 
New Zealand currently has a school-based delivery system that could be easily adapted to 
include both females and males. This would provide a strong framework on which to 
campaign for higher uptake in our younger citizens by enlisting them in this part of the 
immunisation programme. Education for parents about the risk that HPV poses to boys could 
see the current vaccination programme challenged. If parents were educated that their boys 
were at a high risk of contracting HPV, at equal risk as their daughters, there is a possibility 
that they would heavily question why funded vaccines were not being offered to both males 
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and females. Particularly in light of HPV being a male and female disease that can lead to a 
variety of destructive outcomes, whether it is genital warts or an even more destructive health 
issue like cancer, later in life. 
2.10 MALE VACCINATION 
In addition to the hanns of HPV infection for women, there is a wide range of literature to 
suggest that it also causes a burden of disease among men. Elbasha and Dasbach (2010) 
suggest that males are most likely to acquire the HPV swiftly after sexual debut and it remains 
a threat at any time throughout adolescence and adult life. HPV can cause a range of serious 
diseases affecting men, for example penile, anal, respiratory papillomatous, head/neck cancers 
and also genital waiis. Whilst vaccination of females provides some protection to males 
through the principles of herd immunity, men who have sex with other men are not 
benefitting. A comparative study of the prevalence of HPV virus in men concluded that men 
were more at risk of contracting HPV if they were having sex with men than if they were 
having sex with women (Nyitray et al., 2011). 
To date, much of the literature on vaccination of males has focused on cost effectiveness. 
One American study found that the health benefits to males were extensive and that 
financially it was a viable option (Elbasha & Dasbach, 2010). However, another American 
study concluded that it became economical to vaccinate against HPV for males only when 
uptake of vaccination was low in females (Chesson et al., 2011). In their opinion, working to 
ensure females were vaccinated was the better goal. Focused more specifically on the benefits 
of vaccination for the non-cervical cancers, de Kok et al. (2011) concluded that if HPV 
vaccination was to completely prevent all of the non-cervical cancers caused by HPV, then 
there would be a substantial increase in the cost effectiveness of vaccinating not only the 
female population, but the male population as well. 
Initial exploration of the literature has indicated that there is debate as to the benefits and 
costs of HPV vaccination programmes being extended to males. However, at a personal level 
there are clearly health benefits for those who have been vaccinated. There is evidence of an 
effective vaccine that has the ability to seroconvert, with a decline in the contracting of HPV 
for those vaccinated. Although some countries, such as America, are now vaccinating males 
against HPV, in New Zealand the scheduled vaccination programme provides only women 
with access to free funded vaccine against HPV, whereas men can access the vaccine if they 
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are willing to pay. For years affordability and access have been major factors in all health care 
systems, and these factors have created baniers in equity to healthcare. 
Given that there is some evidence the HPV vaccination might prevent a range of other HPV-
related cancers in addition to cervical and that a wider vaccination programme is likely to 
benefit herd immunity and thus protect women further, the topic for this review focuses on the 
advantages and disadvantages ofHPV vaccination for boys. It will be achieved through a 
systematic integrative review of the cunent literature dating back to 2009. It is presently 
becoming a topic of discussion within our health care system as to whether or not males 
should also receive funded immunisation for HPV (MOH, 2014). 
In conclusion, although it has taken over a century for science to establish not only a strong 
link to cervical cancer but to other cancers, we need to entertain the idea that in the future 
HPV could be responsible for a range or variety of other health issues. 
There is cunently substantial evidence to demonstrate that HPV not only affects women but 
men also. There is extensive evidence that the HPV vaccine is an effective vaccine that has 
the ability to sero-conve1i those who have been immunised. There is literature supporting a 
decline in the contraction of HPV for those vaccinated. It appears, however, that although 
some countries such as America are now vaccinating males against the HPV, New Zealand 
has taken a 'wait and see' approach to consider the uptake of a funded HPV vaccination 
programme that includes males. The evidence to date would suggest further consideration 
should be given to including males in the funded immunisation programme. 
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3 Methodology and Methods 
3.1 INTRODUCTION 
Within this chapter discussion will be focused on the method of an integrative review that 
explores the advantages and disadvantages of HPV vaccination for males aged between 9 to 
20 years using a systematic approach. The initial literature search included both qualitative 
and quantitative research and other relevant sources that were deemed appropriate to the 
study. This integrative review used a rigorous and extensive search strategy, inclusion and 
exclusion criteria, and literature which was critically appraised to establish results for analysis 
to conclude whether it would be advantageous or a disadvantage to introduce the vaccination 
of boys with the HPV vaccine. 
3.2 METHODOLOGY 
Research has been a pivotal component to the advancement of health care worldwide (Polit & 
Beck, 2012). Existing literature has often been utilised as the basis of a study or to examine a 
specific research question. Where previously primary research has been undertaken, a 
reviewer may evaluate existing data that has already been published through the process of a 
literature search, to establish their own body of research or to summarise quantities of 
literature to establish a conclusion (Cook, Mulrow & Haynes, 1997). 
The following integrative literature review used a systematic approach; these have taken on 
increasing importance within the healthcare system and are increasingly used for the basis of 
clinical guidelines (Polit & Beck, 2012). A systematic approach allows for the reviewer to 
implement a strategy for data collection, synthesis and conclusions in a manner that reduces 
bias and enables the reviewer to look at large volumes of relevant literature, but condense this 
into a topic specific manageable amount for synthesis and analysis by using scientific tools or 
strategies to ascertain the most relevant literature (Cook, Mulrow & Haynes, 1997). 
This research used a systematic approach to integrate widespread research data for the 
purpose of extraction, analysis and synthesis. 
Meta-analysis is the most robust form of systematic review and considered the gold standard 
method for use when undertaking a review of literature for the purpose of clinical guideline. 
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It uses the process of integrating quantitative studies into statistical findings. However these 
studies need to be very similar or virtually identical in topic and nature for meta-analyses to 
work or be combined into one unit for the purpose of analyses (Polit & Beck, 2012). Whilst 
meta-analysis is the most robust form of review and offers objectivity, it is always focused 
from a quantitative perspective and inevitably the criteria and scope has to be very narrow 
(Polit & Beck, 2012). For this reason a meta-analysis was not the appropriate method for this 
review as the studies identified did not provide data that could be aggregated. 
An integrative review is the broadest type of review, as it can include numerous 
methodologies, including studies using both quantitative and qualitative data, which are more 
commonly found within nursing research (JBI, 2014; Whittemore & Knafl, 2005). 
Whittemore and Knafl (2005) argue that a literature review allows a researcher to take both 
theoretical literature and empirical literature to establish a clearer view or understanding of a 
particular healthcare issue that the researcher may wish to explore. The integrative review 
method can also play an imp011ant role in integrating evidence-based initiatives into a 
practical framework, or explore a rationale for any healthcare initiative (Whittemore & Knafl, 
2005). The reviewer used this method in order to be able to incorporate both qualitative and 
quantitative studies and establish a clear conclusion about the advantages and disadvantages 
of the introduction ofHPV vaccination for boys. 
3.3 METHOD 
Initially the integrative review was to include research from both a qualitative and 
quantitative review. Throughout the review however, no qualitative literature was found that 
met the inclusion and exclusion criteria and this led to the review only including quantitative 
literature. The quantitative literature for the review was not similar enough to warrant using 
meta-analysis. An integrative review was selected to explore the question: What are the 
advantages and disadvantages of HPV vaccine for boys aged between 9-20 years? 
Recent literature was used to establish what data was currently available on HPV programmes 
already implemented, this was achieved through a systematic literature search for data that 
was then collected, reviewed, and synthesised. 
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Numerous websites were reviewed prior to the initial start of the review to establish the 
viability of the study. National and worldwide websites that discussed the vaccination of 
males as well as those that did not were searched. Brief initial searches were also completed 
on the Joanna Briggs Institute (JBI) systematic reviews, Ovid-MEDLINE and the Cochrane 
databases to verify that no previous study had been completed. Colleagues and other health 
professionals including the Southern District Health Board immunisation team were also 
involved through discussion at the outset of the study to establish if anyone was cun-ently 
working on a similar study. 
The Joanna Briggs Institute (JBI, 2011) promotes the use of PICO (Population, Intervention, 
Comparison, and Outcome) to assist the researcher in setting parameters around literature that 
is to be included in the review. The use of PICO assists in the construction of a clear and 
precise question for the researcher when perfonning a systematic integrative review 
(JBI, 2011 ). The researcher used the JBI PICO tool as a basis to establish the parameters that 
would define inclusion and exclusion criteria. 
The following (Table 3 .1) illustrates the use of PICO when choosing key words to base the 
initial database search on. This enabled the researcher to have defined guidelines when 
searching the databases and websites. 
Table 3.1. Criteria considered for the Review will include 
Males 
HPV vaccination programmes 
Population 
Phenomena of interest 
Context HPV vaccination programmes/ boys/men/ or implementation in 
NZ 
Outcomes Advantages/disadvantages of introducing a vaccine programme 
for males from school age 
Studies Qualitative/ quantitative 
3.4 INCLUSION AND EXCLUSION CRITERIA 
Articles included during the review: 
• Published post 2009 until April 2015 
• In the English language 
• Qualitative and quantitative studies 
• Primary research, not reviews of previous studies. 
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• Discuss the advantages/disadvantages or benefits or hanns of HPV 
• Studies had to be centred on HPV vaccination of males 
Articles excluded during the review: 
• Studies that were predominantly about females/girls. 
• Studies predominantly about men over 20 years old. 
• Studies that were not about HPV vaccination in males 
An initial search was conducted to consider all research and literature that was based around 
HPV, its vaccine and implementation of programmes at a worldwide level regardless of 
methodology, giving as broader range of perspectives and findings to later be synthesised. 
It included both qualitative and quantitative literature that was accessed via Otago University 
library user's website to access multiple databases. 
3.5 SEARCH STRATEGY 
A three-staged approach was unde1iaken for the literature search, as recommended by Joanna 
Briggs Institute; with the first stage identifying key words to guide the search (JBI, 2014). 
3.5.1 Keywords 
The initial search of keywords was broken down into four different concepts that were then 
merged with truncation, phase searching and variations of AND and OR as well as against the 
four concepts the researcher checked for synonyms and related terms. The researcher at 
various points checked that the words being used covered all variations of the word and when 
a word of similar meaning was found to be covered by this particular word it was also added 
to the concept that it was consistent with. Once the initial search was complete the keywords 
from miicles that appeared to be suitable to the author were also checked for fmiher keywords 
that may have been missed at the time of initial searching to ensure all terms or definitions 
were included in the search. 
The concepts developed throughout the search phase and those used for the final search were 
as follows: 
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Papillomavirus infection, papillomavirus, HPV, human papillomavirus 
Vaccines, vaccinate, vaccinated, vaccination, papillomavirus vaccines, 
immunise, immunisation programmes, HPV Vaccine, vaccme 
acceptability 
Primary prevention, patient, acceptance of healthcare, health knowledge 
and attitudes, practice, advantages, benefits, disadvantages, pros, cons 
Males, boys and universal 
Access was obtained through University of Otago Library article databases. The following 
databases were searched, CINAHL, EMBASE, Ovid MEDLINE, Web of Science, JBI, 
Cochrane reviews and Scopus. The searching using Scopus produced large amounts of 
literature and there was an inability to define search terms adequately, and was later excluded 
as a result. 
3.5.2 Searching of other resources 
Many other resources were utilised to obtain background research on the topic for a fuller 
understanding. The researcher accessed numerous websites for infonnation regarding the 
disease, its progression, and cmTent HPV programmes for women and males. These were 
accessed via internet and included the following: Google, Ministry of Health website, Centre 
for controlled diseases website (CDC), New Zealand HPV programme, Best Practice 
Guidelines, NICE guidelines, Up-to-date website and Google Scholar. Some sites were 
deemed unsuitable for the actual database search of the integrative review because the 
researcher could not impose limitations on or could not narrow the search to within the 
inclusion and exclusion criteria. 
The aim of a three-stage search strategy is to ensure that all relevant literature is retrieved via 
a systematic approach that will ensure a full and comprehensive set of results (JBI, 2011). 
The first stage of the literature search involved defining the key concepts, with the first 
two concepts run through all databases to establish a body of literature. The second stage 
began with a more comprehensive search using the four concepts together to establish that all 
variations of keywords were implemented in the review. The final results were then reviewed 
with the first stage of searching. 
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The third stage comprised of checking all the reference lists of the chosen articles to ensure no 
other articles had been missed that would be beneficial or crucial to the review. All a1iicles 
were reviewed to establish whether they would contribute to answering the proposed 
dissertation question. 
3.6 SELECTION OF STUDIES 
The search strategy resulted in the identification of a total of 1620 articles found via the initial 
search strategy and two additional miicles provided by the Southland/Otago Immunisation 
Co-ordinator. These miicles included some or all of the four differing concepts shown in 
Tables 3.1 and 3.2 .. Duplications were removed and one was excluded due to having no 
author leaving a total of 1611 articles. Initial screening was achieved with the researcher 
reviewing all titles and excluding further articles that would not address the intended research 
aims. These articles were mostly excluded on the grounds of being found to have a female 
focus or mainly cervical cancer, but had refen-ed to males at some stage. In addition, some 
were literature reviews and these were excluded because the intention of the review was to 
source primary data. Some were found to be outside of the inclusion criteria, for example 
publication prior to 2009. Following this process 1261 articles were removed from 
consideration leaving 350 miicles for more robust reviewing. The abstracts of the remaining 
350 miicles were then reviewed. Where it was not clear that inclusion criteria were met most 
of the miicle was read to establish suitability for the study. A total of 154 miicles were then 
read in full to establish whether they answered the research question and met the final 
inclusion criteria. The exclusion of 145 articles occmTed mainly due to miicles being male 
focused but having an age parameter that went to 26 years rather than 20 years or were 
focused on both genders. At this point nine articles remained. 
The search strategy was documented using PR1SMA flow charts to track the search strategy 
process. PRJSMA (2009) is a researching database that develops a wide range of tools to aid 
the researcher in ensuring that there is clear transparency of a search strategy. In particular 
they provide checklists and flow diagrams that enable the researcher to clearly show how their 
search strategy has been undertaken; for the purpose of clarity this research has used 
PRIS MA' s flow chart to illustrate the search process, refer to Figure 3 .1. 
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The author and one supervisor then critically appraised the nme articles, resulting in 
three articles being excluded from the study for a variety of reasons. One study was 
detennined unlikely to answer the proposed aim of the study, and another article was 
excluded because it was a literature review rather than original research. Six papers were 
concluded to have met with all inclusion criteria. These were critically appraised by the 
researcher and one supervisor to determine that they met 70% of critical appraisal criteria. 
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Figure 3.1. Flow diagram of search strategy 
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3. 7 ASSESSMENT OF METHODOLOGICAL QUALITY 
A critical step for integrative reviews is to evaluate the literature for its quality (JBI,2014). 
This is often completed through a critique of methodological quality for each proposed article. 
For this study each article was reviewed for methodological quality and validity by both the 
primary reviewer and her supervisors. 
JBI assessment and review instruments guided assessment of methodological quality. As the 
review is based on quantitative studies, including some that used economic impact, the tools 
selected were relevant to these methods. The three articles that reported research using 
quantitative methods were reviewed, guided by the tool from Joanna Briggs Institute 
Meta Analysis of Statistics Assessment and Review Instrument (JBI-MASTARI). The three 
papers that had a cost effectiveness or economical component were reviewed, guided by the 
Joanna Briggs Institute Analysis of Cost, Technology and Utilisation Assessment and Review 
Instrwnent (JBI- ACTUARI)(JBI, 2014). 
Three assessors, individually assessed each of the six papers, and then consulted with each 
other to detennine which papers would be included in the study. All three assessors were 
broadly consistent in their assessments adding congruity to the methodological quality of the 
study. 
3.8 DATA EXTRACTION 
Due to the nature of the articles found from the initial search strategy, with three having 
an economic focus and three being of a quantitative nature, the decision was made not 
to use JBI extraction tools for two reasons. The first of these was that due to the varying 
nature of articles it was deemed by the reviewer to be diversifying too much, and 
secondly the tools were to be accessed online, but access difficulties hindered the 
process. Therefore the reviewer used tabulation as a form of extraction with the data of 
all six articles being tabled in two ways, firstly they were tabled with each study's 
information which included author, year of publication, country of origin. The type of 
research that the study was and the method that was used in each study. Included were 
characteristics of the study, limitations and inclusions and lastly the study outcomes(see 
Table 4.1). For the reviewer to get a clearer idea of each study's results, a second table 
was used to extract the main ideas (see appendix. A). 
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3.9 DATA ANALYSIS 
Data analysis is a pivotal pmi of the literature review process as it allows the researcher to 
synthesise emerging findings from the literature and group them into categories for analysis 
(JBI, 2011 ). Analysis for this review required the combination of literature from quantitative 
paradigms, with half of these including economic analyses. Tables 4.1 for the study and the 
table in Appendix A provided initial guidance in synthesising a final set of findings. Each of 
the studies was read multiple times to understand the key points of each miicle. Ultimately 
four main categories were identified as representing the findings from all six studies 
reviewed. These are nmTated in the results section of the study. 
In conclusion, JBI (2014) was used to guide the process of identifying studies for the 
systematic review. The extraction process was based on extraction processes used by 
examining and tabling the findings for analysis. The reviewer was left with four main 
findings from the integrative review process, it is these that fanned the results of the 
disse1iation and which the discussiion for the review is based around. These main findings 
can be found naITated in the results section, followed by a discussion that focuses on a 




This chapter presents a summary of the findings from the six studies that resulted from the 
integrative literature review process. The six studies that were ultimately included for further 
analysis include two published in the United Kingdom (UK), one in France, one m 
New Zealand, one in the United States of America (USA) and one in Australia. 
Initially the author read through all six studies and summarised findings from each of the 
results sections and synthesised findings into four main categories and in some cases further 
expanded these with sub-categories. All six studies were ultimately selected as best answering 
the integrative review research question: What are the advantages and disadvantages for 
vaccinating males under 20 years with the HPV vaccine? 
4.2 RESULTS 
An important finding from the literature review process was that there were no pnmary 
research, interventional or observational studies of successive cohorts addressing the review 
question. Instead the six articles included in the review relied on modelling to estimate the 
advantages and disadvantages of vaccinating males between the ages of 9-20 years with the 
HPV vaccine. These aiiicles did meet the inclusion criteria, and were critically appraised by 
the reviewer and two supervisors. 
All six studies reviewed used simulated models and two of these developed mathematical 
programmes to predict efficacy (Brisson, van de Velde, Franco, Drolet, & Baily, 2011; Brown 
& White, 2010). One further study used a mathematical model to predict results utilising a 
previously developed model (Burger, Sy, Nygard, Kristiansen, & Kim, 2014). Pearson et al. 
(2014) used a markov macro-simulation model which is a model that allows for simulation of 
changing health states over a period of time, allowing for different variables to be imputed to 
establish a set of results, in this case a macro simulation model was used allowing for 
probabilities to be entered to reflect an entire coho1i or large number. Smith and Canfell 
(2014) used a dynamic model that simulated two cohorts, and Maiiy, Roze, Bresse, Largeron, 
and Smith-Palmer (2013) used a Microsoft spreadsheet that was used for inputting data based 
on earlier developed models. 
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Four studies used comparable coh01is on which to base their model with one further study 
using a simulated model to calculate how different variables such as vaccine cost, vaccinating 
boys and girls and the health outcomes that these would have on including males to an 
existing programme. One further study used a markov-macro-simulated model to predict the 
quality of life years that would be gained and to what economic value this would be at, it was 
dependant on a variety of variables for example; herd immunity and future health statistics 
(Pearson et al., 2014). 
All six studies were reviewed and displayed usmg a table fonnat for companson; see 
Table 4.1. 
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Table 4.1. Details of six included studies 
Study (Year) 
Title 
Brown, V., and White, 
K.A.J. (2010). United 
Kingdom. 
The HPV vaccination 
strategy: could male 
vaccination have a significant 
impact? 
Brisson, M., van de Velde, 
N., Franco, E., Drolet, M., 
and Boily, M. (2011). 
United Kingdom. 
Incremental Impact of Adding 
Boys to Current Human 
Papillomavirus Vaccination 
Programmes: Role of Herd 
Immunity. 
Burger, E., Sy, S., Nygard, 
M., Kristensen, I. and Kim, 
J. (2014). USA. 
Prevention of HPV-Related 
Cancers in Norway: Cost-
Effectiveness of Expanding 
the HPV Vaccination Program 
to Include Pre-Adolescent 
Boys. 
Type of Study/Method 
Quantitative 
Using mathematical model to 
check for efficacy 
Quantitative 
Developed a mathematical 
model to predict cost efficacy 
of vaccination in both males 
and females . 
Quantitative 




Characteristics of Model 
" 
Has developed a model that 








Uses many variables to 
calculate the health outcomes 
and costs of different 
vaccination scenarios, 
including female and male 
vaccination with the HPV 
vaccme. 
... , ---i - .... 
Outcomes 
Results show that waning 
immunity plays a large factor 
in allowing infection to 
persist. 
Concludes that infection 
reservoir occurs through 
males. 
Vaccinating males showed 
reduction in HPV incidence 
over 70 years. However 
showed that the benefit of 
vaccinating males decreased 
with an increased uptake of 
females having vaccinations. 
Results showed that vaccine 
pricing contributed to whether 
or not vaccination for both 
males and females would be 
cost effective. Results 
conclude that males should 
only be added to the 
vaccination programme if 




It is a mathematical equation 
and possibly requires more 
data variables inputted and 
outputted and for answers to 
be studied in "real word" 
Weakness: Makes key 
assumptions of different 
values when using a variety of 
variables that are entered into 
model. 
Study is based on assumptions 
and actuals and also model is 
developed to fit Norway's 
systems/cost structure. 
Assumption can vary 




Marty, R., Roze, S., 
Largeron, N., and Smith-
Palmer, J. (2013). France. 
Estimating the clinical 
benefits of vaccinating boys 
and girls against the HPV-
related diseases in Europe 
Pearson, A., Kvizhinadze, 
G., Wilson, N., Smith, M., 
Canfell, K., and Blakely, T. 
(2014). New Zealand. 
Is expanding HPV vaccination 
programmes to include 
school-aged boys likely to be 
value-for-money: a cost-utility 
analysis in a country with an 
existing schoolgirl 
programme. 
Smith, M., and Canfell, K. 
(2014). 
Incremental Benefits of Male 
Vaccination Accounting for 






.,. -I ';' 
Quantitative 
Uses models that have been 
developed earlier to input 
data. 
Uses Microsoft excels spread 
sheet for inputting data. 
Macro-simulation model. 
A Markov macro-simulation 
model was used which made 
adjustments for herd 
immunity, future health 
statistics incl: cervical cancer, 
pre-cancer etc., was based on 
12yr old boys scenario. 
Quantitative 
Dynamic model simulated 




Both males and females. 
' '( 




Health sector costs, simulated. 
Quality-adjusted life-years 
(QALYs). 
Based on New Zealand health 
system. 
Two cohort groups using 
simulated model to determine 
if differing factors affected 
vaccine uptake. 
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Screening of girls alone had 
an 80% decrease in 
..., 
carcinomas, vaccinating boys 
a 61 % decrease and together 
both sexes concluded a 90% 
reduction in disease. 
Vaccination of boys was not 
found to be cost-effective if 
including them in a girls only 
HPV vaccination program in 
NZ. For cost effectiveness 
vaccine would need to be 
cheaper. 
Results showed the population 
incremental impact of adding 
males was lower if vaccine 
uptake was correlated. 
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Assumes certain parameters, 
which then extrapolates the 
data to determine disease 
reduction. 
It is computer simulation so 
disease reduction is an 
assumption. 
Simulated theory. Based on 
many variables. Can be 
limitation depending on 
realisticness of simulation. 
Results can only be as 
accurate as the assumptions 
that they make about some of 
















4.3 ANALYSIS OF RESULTS - MODELLING HPV VACCINATION FOR BOYS 
4.3.1 Category One: Decrease in HPV 
All six vaccination modelling studies predicted a decrease in HPV infection as a result of 
HPV vaccination of males. The decrease was attributed to various reasons including 
vaccination (Brisson et al., 2011; Brown & White, 2010; Burger et al., 2014; Marty, Roze, 
Bresse, Largeron, & Smith-Palmer, 2013; Pearson et al., 2014; Smith & Canfell, 2014), 
vaccination coverage (Brown & White, 2010; Marty et al., 2013; Smith & Canfell, 2014) and 
social factors (Smith & Canfell, 2014). Each of these reasons contributed to the main finding 
of predicted decrease in HPV. Furthermore all six studies predicted that vaccination of males 
would lower HPV vaccinated diseases. 
Whilst female vaccination alone was shown to result in substantially decreased HPV infection 
and disease (including cancer) in both males and females (Brisson et al., 2011; Brown & 
White, 2010; Burger et al., 2014; Marty et al., 2013; Smith & Canfell, 2014). 
Male vaccination in addition to female vaccination was predicted to further reduce HPV. 
Brisson, van de Velde, Franco, Drolet, and Boily (2011) showed adding male vaccination to 
female vaccination resulted in a further 20% reduction in HPV. In comparison Smith and 
Canfell (2014) found the effect to be slightly less at around a further 10% reduction. 
However, all articles did conclude that there would be increased benefit clinically if males 
were to be added to HPV vaccination programmes. Brisson et al. (2011) used their model to 
predict that vaccinating 12-year-old girls showed a rapid reduction in HPV by 65% for 
females and 62% reduction for males. Brisson et al. (2011) further used their model to 
include boys at the same age and circumstance, predicting a further reduction to 85% for 
females and 88% for males, calculating that there would be reduction with female vaccination 
but this was in fact reduced significantly more with the inclusion of males. This was 
supported further by Smith and Canfell (2014) who considered that the vaccination of males 
decreased the likelihood of HPV in all sub-groups or varieties of HPV related cancers and 
drew attention to a large decrease in HPV 16 which is often associated with genital warts 
(Smith & Canfell, 2014). Brown and White (2010) used modelling to depict the reduction of 
HPV but further showed that the eradication of HPV was not possible unless there was an 












4.3.2 Category Two: Disease outcomes 
Four studies (Brisson et al., 2011; Burger et al., 2014; Marty et al., 2013; Pearson et al., 2014) 
showed findings that contributed to HPV disease related illnesses. These were broken down 
into two different sub-categories genital warts and HPV related cancers. 
4.3.2.1 Genital Warts 
Reduction in genital warts was a primary focus for the cost/benefit evaluations and was 
described in all of the studies reviewed as a main finding. However only three studies 
discussed genital warts in depth, with two studies describing a significant reduction in genital 
warts with female vaccination alone and suggested this was reduced significantly more when 
male vaccination was introduced for both males and females (Burger et al., 2014; Marty et al., 
2013; Pearson et al., 2014). 
Three studies determined throughout their modelling that the effectiveness of HPV 
vaccination was better for HPV 6/11 that was the main contributor of genital warts (Burger et 
al., 2014; Marty et al., 2013; Pearson et al., 2014). Three studies concluded that male 
vaccination helped reduce genital warts for both females and males (Brisson et al., 2011; 
Brown & White, 2010; Smith & Canfell, 2014), with another author determining that by 
including male vaccination genital warts would decrease by 89% for males and 91 % for 
females (Marty et al., 2013). 
Burger, Sy, Nygard, Kristiansen, and Kim (2014) also support this theory through the use of a 
simulated model by considering gender-neutral vaccination with a decrease in genital warts 
by 85% for females and 84% for males. Marty et al. (2013) also allude to some cross 
protection of non vaccinated HPV diseases through HPV vaccination determining that there 
would be a 5 8% decrease for females and 71 % decrease for males of non vaccinated variants 
ofHPV by including male vaccination. 
4.3.2.2 HPV related cancers 
HPV related cancers referred to cervical, head, neck, penile, anal and all other related cancers 
caused by HPV infection. Marty et al. (2013) found that female only vaccination programmes 
reduced cervical cancer by up to 85% and that by including male HPV vaccination it would 
increase this to 96% providing further protection. Marty et al. (2013) further discussed 











It discussed and compared female vaccination, male vaccination and compared these with 
screening rates. Results suggested that there was an 84% decrease for females and a 61 % 
decrease for males with female only vaccination and that HPV related cancers reduced by 
86% in males when vaccinated compared with screening results alone (Marty et al., 2013) . 
The study postulated how extending vaccination to males had the ability to decrease HPV 
related cancers by 65 % (Marty et al., 2013). Marty et al. (2013) concluded that the greatest 
impact seen by vaccinating males as well as female was head and neck cancers decreased by 
88% as opposed to 65% when only vaccinating females. 
Two studies discussed the impact that male vaccination would have on penile and anal 
cancers concluding that the inclusion of males with the HPV vaccine would reduce penile 
cancer from 68% to 18%. Furthermore anal cancer reduced by 63% for female HPV 
vaccination only contrasting with an 86% reduction for both female and male vaccination 
programmes (Burger et al., 2014; Marty et al., 2013). 
4.3.3 Category Three: Results of cost benefit analysis 
Three articles used cost benefit analysis through modelling simulation to consider whether or 
not to vaccinate males (Brisson et al., 2011; Burger et al., 2014; Pearson et al., 2014). Cost 
benefit analysis was determined as both the financial cost involved in vaccinating an 
individual with the HPV vaccine versus the cost of a person contracting HPV disease itself or 
the progression of HPV to other disease states. The three studies further evaluated that this 
was based on many factors. These three studies used simulated theories that included 
benchmarking the cost of giving the HPV vaccine across a population of males against the life 
years that would be saved if they didn't contract HPV disease or disease states caused from 
HPV progression these were referred to as quality oflife years (QALYs). These QAL Ys were 
used to aid in the conclusion of cost effectiveness of a vaccination programme for males. 
There were distinct advantages and disadvantages and several factors that were determind to 
contribute towards cost. Cost was evaluated throughout the studies in a variety of ways with 
articles evaluating the cost of HPV vaccination that established parameters around HPV 
vaccination and used different variables and values to help establish at which point it would 
be useful to vaccinate males with the HPV vaccine. This category was broken up into three 





Three studies used modelling to predict the quality of life years (QAL Y) achieved and the 
cost of these for both male and female vaccination with HPV vaccine. Burger et al. (2014) 
and Pearson et al. (2014) in particular focused on the incremental value that male vaccination 
would give to HPV vaccination. Pearson et al.' s (2014) model predicted that when increasing 
coverage of both females and males the cost of the intervention's used (eg., an increase in 
vaccine, time and associated costs, compared with the QAL Y s gained) would not be 
beneficial, and that with the increase in coverage the expense also increased. Pearson et al. 
(2014) also concluded that adding males to an already established female vaccination 
programme offered a similar number of QAL Y s, but with greater cost. This cost for male 
vaccination was also increased if the current female programme was an existing intensified 
programme as the males would have already had some coverage from herd immunity when 
the existing programme was intensified. The study by Burger et al. (2014) supported this by 
determining that expanding vaccination of HPV to boys with an already existing girls 
programme was not cost effective or considered good value for money (Burger et al., 2014). 
Brisson et al.'s (2011) dynamic model showed that the vaccination programme returns on 
girls was higher than that of males. This was thought to be due to herd immunity that is 
acquired by males through the vaccination of females. When males are added to the 
programme then the cost benefit effect of this begins to lessen as the cost of each individual 
vaccine must be accounted for. This finding was also supported by Burger et al. (2014) who 
concluded that it would not be value for money (Brisson et al., 2011; Burger et al., 2014; 
Pearson et al., 2014). 
4.3.3.2 Advantages 
When considering cost, some benefits from additional male vaccination were found, but these 
were focused on the health benefits as opposed to it being value for money. Two of the 
selected studies, Brisson et al. (2011) and Burger et al. (2014), determined that there were 
health benefits to be gained by including males, while Pearson et al. (2014) concluded that it 
would be more cost effective to intensify a girls only programme to establish those health 
benefits at a more cost effective rate. Pearson et al. (2014) concluded that if boys were to be 
vaccinated at the current rate girls were, it would cost approx $117,000 per Quality of Life 
Year(QALY) gained from vaccination, compared with $83,000 for female vaccination, 







4.3.3.3 Factors contributing to Cost 
Three studies described vaccination costs as being critical to whether male vaccination would 
be beneficial (Brisson et al., 2011; Burger et al., 2014; Pearson et al., 2014). Pearson et al. 
(2014) concluded through modelling that even with low vaccination costs it would not be cost 
effective to vaccinate males. This contrasted with two studies which concluded that if vaccine 
and administration costs were low enough then simulated models demonstrated that it would 
be cost effective to vaccinate males. Burger et al. (2014) and Pearson et al. (2014) concluded 
that when considering cost and QALY, several factors changed value depending on whether 
the model used included only cervical cancer outcomes, or if including all HPV related 
cancers. Burger et al. (2014) considered that when a dose of vaccine was valued at $7 5, the 
QAL Y varied from between $20,600 for cervical cancer HPV disease consideration, or 
$5,000 if also including all cancers and genital manifestations. This study also concluded that 
the vaccine cost was key to a male vaccination becoming cost effective. 
4.3.4 Category Four: Variables considered in the studies 
The results of the six studies had multiple assumed variables used to predict results. Pearson 
et al. (2014) argued that the overall uncertainty ofHPV reduction was the main sensitivity and 
created extreme uncertainty when establishing the effect and value of adding males to a 
female vaccination programme (Pearson et al., 2014). 
Another variable was vaccine efficacy that each study assumed when using their simulated 
theories. In four of the studies, a vaccine efficacy of 99%-100% was assumed. One study used 
vaccine efficacy as a variable in different scenarios(Brown & White, 2010), and another study 
did not state what vaccine efficacy was used (Brisson et al., 2011; Burger et al., 2014; Marty 
et al., 2013; Pearson et al., 2014). Vaccine efficacy was a variable that both Brisson et al. 
(2011) and Brown and White (2010) used or discussed with both studies concluding that if 
efficacy increased then HPV decreased. Brisson et al. (2011 ), showed that this was less 
beneficial for males when vaccine efficacy was decreased, and further determined an HPV 
disease increase, showing that under this scenario it would be beneficial to vaccinate boys. 
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Vaccine pricing was another issue that several authors discussed as being an integral factor in 
cost effectiveness of introducing the HPV vaccine to males, with general consensus that the 
lower the vaccine price the more economical vaccinating became (Burger et al., 2014; 
Pearson et al., 2014). 
4.3.4.1 Vaccine Coverage 
Assumed vaccine coverage was considered as a variable by all of the six studies reviewed. 
Vaccine coverage is the term used to describe the total proportion of people within a 
population that are vaccinated, and this is often demonstrated or discussed as a percentage. 
Vaccine coverage was specifically considered in four of the modelling studies, concluding 
that the inclusion of male vaccination substantially increased population coverage (Brisson et 
al., 2011; Brown & White, 2010; Marty et al., 2013; Smith & Canfell, 2014). 
Vaccination coverage was estimated using scenarios where there was 50% (Smith & Canfell, 
2014) or 70% variations in coverage (Brown & White, 2010; Marty et al., 2013) to simulate 
disease reduction. Coverage was predicted at the same level when simulating male 
vaccination or the inclusion of male vaccination as was used for female prediction prior to 
male vaccination being added to model. Results concluded that when vaccination coverage is 
poor or low, it influenced the prevalence of HPV disease (Brisson et al., 2011; Brown & 
White, 2010; Burger et al., 2014; Pearson et al., 2014; Smith & Canfell, 2014). Brown and 
White (2010) demonstrated with a mathematical equation model that males form a reservoir 
for HPV to remain active and that HPV eradication would only be possible if male 
vaccination was to be included. Brown and White's study (2010) also considered the effect of 
waning immunity over time within its simulated model and postulated what part this could 
play in HPV persistence. 
4.3.4.2 Herd Immunity 
The effect of herd immunity was well documented in most articles and for narration was 
broken into three different sub categories, males, females, and both females and males, to 
make it easy to define similarities. Pearson et al. (2014) found that males benefitted from 




One study showed that when female coverage is low, herd immunity is very low. It further 
concluded that when female coverage was high there was very small benefit to be gained for 
herd immunity with vaccinating males (Smith & Canfell, 2014). 
Marty et al. (2013) discussed the impact on herd immunity when vaccinating both males and 
females. The study concluded that by vaccinating both males and females with HPV vaccine 
the overall prevalence of genital warts would decrease by 71 % as opposed to 58% if only 
females were to be vaccinated (Marty et al., 2013). In the study it found that the vaccination 
of both boys and girls would give additional disease protection through herd immunity to both 
males and females (Marty et al., 2013). 
4.3.4.3 Social Factors 
A number of other co-related factors were also considered in Smith and Canfell's study. 
These included the nature and behaviour of social groups, and inequalities that could affect 
vaccine coverage, uptake or rate of contraction of HPV. Smith and Canfell's (2014) study 
was the only study to consider this relationship of correlated factors. Smith and Canfell 
(2014) concluded that female only vaccination programmes showed a decrease in HPV 
disease by 56% however this was reduced to 49% for those that had certain correlated factors. 
Groups that had correlated factors had less of a long term reduction, showing that correlated 
factors have an impact on HPV reduction. Smith and Canfell (2014) found that including 
male vaccination increased both vaccination coverage of females and males. However, they 
also found it increased coverage for groups that had correlated factors and resulted in lower 
HPV prevalence of HPV of 60-61 % across all diversities. They also predicted through 
modelling that if there were no corelated factors to consider that including male vaccination 
would incur a decrease ofHPV of 79% amongst males and females (Smith & Canfell, 2014). 
In conclusion, the results from analysis of six modelling studies clearly showed three specific 
main points. Firstly, in all six studies, vaccination with the HPV vaccine postulated decreased 
HPV infection, this was further decreased with the inclusion of males in vaccination 
programmes. The second main point related to changes in disease outcomes with vaccination, 
with all studies showing a decrease in genital warts and other HPV related diseases, 




Thirdly, three of the studies concluded that it was not a cost effective exercise to additionally 
vaccinate males for HPV under current circumstances. However this was based on modelling 
and perceived variants including duration and efficacy of the vaccine itself. In general it 









This chapter will consider the main findings and identify limitations from the literature 
review. It will examine the significance of these findings and how they relate to wider 
literature and discuss the implications for practice and further research. The key purpose of 
this literature review was to evaluate the advantages and disadvantages of vaccinating males 
with the HPV vaccine at a population level, and its implications. 
5.2 FINDINGS OF LITERATURE REVIEW 
It is widely accepted that HPV is the cause of numerous diseases (CDC, 2015; HPV Project, 
2015; WHO, 2015) and is as much a health issue for men as it is for women. It has taken over 
a century to recognise the full impact that HPV can have on an individual and establish the 
links that it has to cancers. Much focus has been on the vaccination of women due to the 
early links that HPV has with cervical cancer. However, it is now widely established that for 
men there are also links to a variety of cancers. It is further accepted that there are three 
vaccines that can stop the contraction and spread of some HPV sero-types through the use of 
Cervarix™, Gardisil quadravalent™ and Gardasil 9vHPV™. One of the main findings from 
this integrative review was that vaccination programmes using these vaccines do in fact 
decrease HPV. The second main finding was the impact they have on HPV disease itself and 
its progression. The third main finding was that including males in any vaccination 
programme at current costs was generally not cost effective. There were a variety of other 
factors when considering vaccination programmes for HPV that were raised, with the main 
ones being efficacy of the vaccination, coverage and the impact that social factors can have on 
uptake of vaccination. 
5.3 LIMITATIONS 
All studies included in the initial scope of the literature review were confined to the English 
language and it is possible that other relevant studies have been reported in other languages. 




Earlier studies may have included earlier theories, frameworks or literature that could have 
been relevant, to the review, however it could possibly be that these would be based only on 
modelling. There is a chance that through year limitation primary research or observational 
studies could have been overlooked. 
Another limitation was that no primary research, interventional or observational studies met 
the final inclusion criteria for further review. All six articles finally included were based on 
simulated models. It will take a number of years for 'real life' data to become available as the 
first HPV vaccination programme only begun upon its licensing in 2006 (MOH, 2015). 
Another main limitation of the study was that all the studies reviewed had multiple and 
different variables, in which their study was based on. However these variables were 
hypothetical in nature leaving doubt as to how they would actually stack up in 'real life'. 
No studies were found that compared the different types of HPV vaccine and the focus 
instead was on females versus universal or male vaccination. By diversifying a simulated 
model to see how different types of HPV vaccines compared, it could show different options 
for any future developments, and possibly show the most cost effective way to giving full 
population vaccination. 
5.4 AREAS FOR FURTHER RESEARCH 
The first and foremost area for future research is to gam data from primary research, 
interventional or observational studies in order to establish both the short term and long term 
effects that HPV vaccination will have on a population. Currently there is only a limited 
amount of 'real life' data related to HPV vaccine efficacy and it is centred on the decrease of 
genital warts within a small population of family planning clinics and sexual health clinics 
based in New Zealand between 2009-2012 (MOH, 2014). 
All six articles reviewed identified that a high percentage of the targeted population needed to 
be vaccinated in order to benefit from herd immunity and decrease the prevalence of HPV 
infection. Currently, New Zealand has HPV vaccination rates of approximately 47% 
(Blakely et al., 2013). This is well short of the 80% that Fine, Eames, and Heymann (2011) 
identified as necessary to achieve herd immunity for a vaccine preventable disease, however 
they do note that by selectively targeting highly transmitting groups the rate could be lower 
(Fine, Eames, & Heymann, 2011). New Zealand currently targets the most at risk groups 
aiming to vaccinate females before they are sexually active by introducing HPV vaccination 




However, it is controversial that they offer this only for females when the at risk group would 
extend to males too. Doing so creates a reservoir for HPV to transmit through and males 
without access to a funded vaccine. For future research, it could be beneficial to increase 
New Zealand's vaccination rates to establish both individual immunity for women, helping to 
create herd immunity that could extend to the male population. For this to occur New Zealand 
needs to reassess how to educate and reach the target population and look at strategies that 
would educate, and promote this vaccine to lift national levels. Vaccination rates are always 
of concern in a current or developing programme. Cmrently, HPV vaccination rates in 
New Zealand are not considered high even though most of the delivery is through a school 
based system, with specialised teams attending to prospective vaccinee's at school. Further 
research is needed to understand why New Zealand's delivery of the HPV vaccine is not 
resulting in an 80% vaccination rate, especially when the delivery is based around ease of 
access for people who work and possibly a reliable way to get education through to 
individuals and to parents. 
Only one of the studies included in the present review considered social factors in relation to 
vaccination and herd immunity (Smith & Canfell, 2014). Vaccination is often considered as 
an essential measure of herd immunity. Smith and Canfell, 2014 offer a new dimesion to this 
by discussing corelated factors that contribute to the success of vaccination. An area for 
further research could be to consider the social impacts on HPV vaccination and an essential 
measure could be a decrease in HPV or HPV related diseases, however this would once again 
take some primary research to prove. Given that the HPV programme has only been running 
in New Zealand since 2008, New Zealand has not yet achieved a high proportion of the 
population vaccinated (New Zealand HPV Project, 2015). There is a future need to increase 
New Zealand's immunisation up take rates to help establish some herd immunity against 
HPV. 
Two studies argued that the most cost effective way of protecting both sexes from HPV 
would be to increase vaccination rates of females (Burger et al. 2014; Pearson et al, 2014). 
However, it has been argued that by including males there is an increased chance of creating 
herd immunity, which is known to improve the chances of stopping outbreaks of any 
vaccinated disease (Salathe, 2015). It could be argued that by allowing universal vaccination 
to be funded for both sexes, coverage across the whole population would offer protection to 
those unvaccinated and would cover the entire highly transmitting demographic rather than 
just females, and aid in achieving an 80% vaccination rate. 
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There are also potential benefits to populations like men who have sex with men, who under 
the current regime would not be funded for vaccination against HPV. The area of herd 
immunity needs fu1iher research in tenns of the HPV vaccine in order to determine which 
populations are better targeted for any vaccination programme in order to achieve herd 
immunity. Future research around this topic would be useful if extending to men who have 
sex with men. 
As discussed in the background chapter a large amount of literature indicates the success that 
Gardasil™ (MOH, 2014), has been having on genital wmis for both females and males, 
therefore, possibly securing its place as a preferred vaccine for HPV related diseases. 
However in February 2015, the Advisory Committee on Immunisation Practices (ACIP) 
promoted a new vaccine for the prevention of HPV disease. This vaccine was a form of 
Gardasil™ which contained protection against a further five strains of HPV. The vaccine 
known as 9vHPV™, contains all serotypes covered by the Gardasil quadrivalent™, and 
further included protection against serotypes 31, 33, 45, 52 and 58. These strains are known 
to be responsible for a higher proportion of HPV related cancers (CDC, 2015). The addition 
of 9vHPV™ now allows for three different vaccines that can vaccinate against HPV 
disease. This exposes a new dimension to explore when considering factors surrounding both 
HPV vaccination of females and universal vaccination programmes. 
Gardasil's 9vHPV™ costs an extra $13 per dose more than that of Gardasil quadrivalent™. It 
is noted on the Centre for Disease Control and Prevention (CDC) website that this new 
vaccine is more cost effective than other HPV vaccines. CDC (2015) discusses when 
considering quality of life years (QALY) that 9vHPV™ was never more than $25,000 with 
any given scenario. 
With this infonnation it could be argued that males would become cost effective to vaccinate 
with this new vaccine. However literature on 9vHPV™ vaccine itself states that this vaccine's 
five extra serotypes are responsible for only 10% of HPV attributed cancers (CDC, 
2015). Gardasil quadrivalent™ contains serotypes 16 & 18 and these have been identified as 
responsible for 64% ofHPV attributed cancers (CDC, 2015). 
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Whilst there could very well be merit in the use of 9vHPV™ vaccine due to the extra 
protection for HPV related diseases, it is also said that the five extra serotypes that are 
covered account for a larger proportion of female related cancers so could actually make it 
more cost effective for females as opposed to males. Using simulated theories may actually 
indicate that it is still only cost effective for females as those five extra serotypes are the cause 
of cervical pre cancers, meaning that 9vHPV™ could possibly benefit females more than 
males (CDC, 2015), however for future research it is an avenue w01ih exploring. 
The use of only two options for HPV vaccination, Gardasil™ or Cervarix™, has been 
considered (WHO, 2015). However throughout the literature review no studies considered 
the cost effectiveness of using only two doses for males and the effect that this could have on 
disease reduction or the benefit that could be given for males. The World Health 
Organisation (2015) raised the possibility of a vaccination schedule that would include two 
doses with the HPV vaccination, or the schedule for vaccination having longer intervals for 
delivery. This could decrease the cost of the HPV vaccine overall, and could increase access 
and convenience for parents, individuals or health providers delivering vaccines. If using less 
vaccine, for example two doses, were a feasible option to giving immunity against HPV then 
it could make the vaccine a more affordable option for all countries, and individuals and could 
in tum help increase vaccination coverage at a community level or even a global level. 
The World Health Organisation (2015) does concede that the studies on HPV are small when 
it comes to delivery of the two dose method and lengthening of intervals between each 
individual dose. At present the reliability or effectiveness of long term protection is not 
known. Further research is needed and could be key towards justifying cost effectiveness of 
the vaccine if proven to provide immunity or health benefits against HPV and for a duration 
of time. In the future, consideration could be given to a universal two dose scenario for both 
females and males, making the cost of female vaccination less and covering males as well to 
ensure equality. 
Another factor often predicted in the simulated theories is the impact that the HPV vaccine 
itself has on the spread of HPV related diseases. There is some literature to suggest that HPV 
vaccine, which includes serotypes 6 & 11, is very effective against the development of genital 
waiis. However, there is very little current research that can definitively state that Cervarix, 
Gardasil, or 9vHPV are going to decrease or eradicate HPV related cancers in those who are 
vaccinated fully. 
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Simulated factors such as waning immunity or the longevity of immunity, pattern of spread, 
and the effectiveness of HPV vaccine, could be major factors in real life scenarios in 
future. Fmiher research is needed on these contributing factors to ensure more accurate data 
in which to make appropriate changes to vaccination programmes. 
None of the six articles discussed vaccination in relation to education and since this area was 
overlooked by all the studies it would be an avenue for future research, as education is pivotal 
towards increasing vaccination rates and awareness about HPV and its related diseases. 
5.5 IMPLICATIONS FOR FUTURE PRACTICE 
Ethical issues smTounding all aspects of health are controversial, and this is expected due to 
individuals offering different opinions, usually formed around competing values associated 
with health, public funding that is available, access or the health benefits proven from specific 
health initiatives. The focus of this literature review was to establish the advantages and 
disadvantages of vaccinating males with the HPV vaccine. Throughout this study much focus 
has been on the vaccination of males in addition to females, and the cost effectiveness of this, 
versus health benefits to be gained. All six studies included in the final review predicted that 
HPV vaccination reduces the incidence of HPV related diseases, but that this is at a 
substantial cost. This cost versus benefit is predicted to increase significantly for males in 
particular. However when considering future practices it could show that we should be trying 
to significantly increase our female vaccination rates to try and establish some herd immunity 
for males. As primary research is developed we may find that it becomes very clear to 
vaccinate males especially if the long term effects of HPV vaccination are proven better with 
a significant decrease in HPV related diseases. 
With each HPV vaccine given there is always a risk to be considered. CDC (2015) noted 
some local reactions can occur with vaccination including redness, pain or swelling at 
injection site. More serious side effects to the vaccine can include nausea, headaches, fever or 
muscle and joint pain, or more seriously anaphylaxis. The risk for these is considered 
minimal (CDC, 2015; Immunisation Handbook, 2015). The literature reviewed did not 
consider wider issues, such as whether women are being asked to bear the risks of 
vaccination, while males might benefit through herd immunity. 
It could be argued that females get the health benefits associated with this risk, but should 
equal rights not be considered when it comes to both health benefits and the risks associated 
with these by offering a funded vaccine for both females and males. 
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It will be interesting for future research to establish whether or not the financial benefits that 
are expected in the reduction in cancers ( especially cervical) are as high as is hoped. If it 
were found that the impact on cancer is not as considerable as the simulated models show, 
this could lead to a review of the vaccine for females. There has been some evidence of cross 
protection between the vaccine preventable HPV and other serotypes that there currently is 
not a vaccine for. It will take time before the results towards these HPV diseases are seen. If 
they did occur, or if there are distinct links in the future between throat, head and neck 
cancers, especially for females with vaccination, it would be an immensely positive 
unintended consequence of the vaccination. However such findings would possibly cause 
controversy, and raise questions as to why the males in the population were not funded for 
this with research clearly indicating at this stage it can give immunity to a number of different 
cancers for both genders. The implication for this in future practice should be focusing on 
educating people on an individual level to ensure they can make an informed choice for a 
funded vaccine or to purchase a vaccine if not funded (Immunisation Handbook, 2014). 
As demonstrated in the background chapter, justification for vaccinating females only is due 
to HPV s link with cervical cancer. However it is also well documented in literature that HPV 
serotypes 6 and 11 are the main cause of genital warts (CDC, 2015; Immunisation Handbook, 
2014; New Zealand HPV Project, 2015). In other words it is not only cervical cancer that 
women will be protected against, should they opt to have the funded vaccine, but also genital 
wmis. Vaccinating women is thus seen as a means to decrease cervical cancers as well as 
genital wmis, with the latter expected to have an impact on their incidence amongst 
heterosexual men. Understandably, although not potentially life threatening, genital wmis can 
cause embarrassment and stress to an individual, and be difficult to adequately treat. If males 
and females were to both be offered a funded vaccine then it is sensible to recognise that 
treatment for this pmiicular STI would not be needed providing a person is vaccinated, 
however that would not include other STis. If a free and funded vaccination was to be offered 
to both sexes, then this would be a more ethical approach to this physical health concern and 
it would also save all individuals from what could be considered an invasive treatment both 
mentally and physically. I would suggest the cost argument, is more about health budget 
spending as opposed to health benefit gains. 
All six studies included in the literature review discussed the cost of HPV vaccination which 





Vaccine price threshold was explored on numerous occasions and a fundamental theme that 
became apparent is that vaccine price contributed to cost effectiveness hugely. Throughout 
time, vaccines have often become more cost effective and if at present vaccination of males is 
not cost effective, it may be a point to revisit in the future, especially if the cost of vaccine 
reduces. 
All six aiiicles included in the literature review were based on simulated models that were 
used to either assess the cost effectiveness of the HPV vaccine for males or to detennine how 
a variety of factors influenced the spread of HPV disease. Some models were more robust 
than other models due to clarity of variables used. With the use of simulated models many 
factors were considered by the author to be omitted such as the value on immunity. For 
example, when a simulated model used immunity of over 20 years, it was a simulated 
theory. Presently there is very little proof that the HPV vaccine does not have waning 
immunity and it could be found that HPV requires a booster in years to come. This is a point 
that health practitioners should be aware of as there could be occurrences of genital waiis for 
the vaccinated populations, or an increase in HPV related diseases later, the implications for 
this would need to be providing this feedback to practitioners, in order to be vigilant around 
early recognition of any HPV related diseases in vaccinated individuals. Reporting of any 
occmTences in disease could be made by health professionals through the Centre for Adverse 
Reactions Monitoring (CARM). 
Vaccine coverage c01Telates to the success of vaccine programmes and herd immunity. 
The literature review has shown that whilst HPV programmes are known to decrease HPV, 
the most cost effective scenario for coverage is herd immunity which is provided by a high 
coverage of vaccinated females. In New Zealand vaccine coverage is currently at 
approximately 47% (Blakely et al., 2013; MOH, 2015) for females only. For herd immunity 
to occur vaccine coverage would need to be over 70% to have an impact on males. For an 
increase in HPV vaccine coverage to occur there would need to be a nationwide drive. 
Currently, programmes are run through schools, and for unknown reasons coverage is still 
low. Health promotion would need to be considered for this to be lifted to increase 
vaccination rates. Social media is a huge factor in the promotion of HPV vaccination and 
there is recent literature that discourages the vaccination against HPV and wrongly insinuates 
the hannfulness that the vaccine can cause. Although reputable websites like CDC discuss 
these issues or insinuations, many people would not know which sites they need to view to 
get non-biased infonnation, or access to evidence based research, avoiding bloggers and non-
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professional opinions. Education sun-ounding the safety and disease progression of HPV 
would be needed to combat some of the negativity that can be found via websites. 
A health promotion consideration could be to utilise more social media for promotion and to 
dispell myths smrounding the risks of not being vaccinated. This may help negate some of the 
cun-ent literature available that is opinion rather than research based that is discouraging HPV 
vaccination. 
An intensified programme that included both females and males would help increase 
vaccination rates and extend to a community level with a raised awareness of HPV as a health 
issue. New Zealand Best Practice Guidelines (BPAC, 2012), are often used as a source in 
decision making not only at a national level but at a primary care level and it would be good 
to see these developed more to see support for a funded HPV vaccine for males given the 
disease burden that it can cause. However, another scenario that could be considered is for the 
vaccine to be offered universally in the hope of attaining at least 50% coverage across all 
entities. By vaccinating males as well as females it could equate to larger numbers being 
vaccinated giving some extra herd immunity benefits and with the inclusion of males it could 
offer some herd immunity to the female demographic who aren't vaccinated 
The integrative review has highlighted that Gardasil™ vaccine is effective in lowering the 
incidence of HPV disease. However it has also detennined that the cost effectiveness for 
male vaccination is not cost effective therefore making it look unlikely that a funded HPV 
vaccine will be added to New Zealand's schedule anytime soon. This presents insight into 
future practices, or implications for practice. As a practice nurse with this knowledge it has 
highlighted the need to educate and promote female vaccination that is available on the 
New Zealand immunisation schedule to try and increase female vaccination rates to give the 
best protection we can through herd immunity for males within the New Zealand setting. 
Cmrently, awareness of the HPV vaccme is driven and centred on female vaccination. 
If male vaccination were included in the immunisation schedule, it would be an opportunity to 
educate parents of both males and females about HPV disease burden, regardless of their 
child's gender and this would lead to increased awareness of HPV and its role in causing 
disease and cancers, should the body's own immune system not provide adequate antibodies. 
It could also lead to more education sUffounding HPV and its diseases and increase rates of 
vaccination to combat this. This view is consistent with Salathe (2015) who argued that while 
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there are communities that harbour strong opposition to vaccination, there will always be 
outbreaks of vaccine preventable diseases, which leaves a reservoir for these diseases to be 
transmitted through. Salathe (2015) argued that this would still occur even if herd immunity 
levels are achieved, lending weight for the need for education sun-ounding vaccination not 
only for HPV but for vaccination in general. It also lends weight for an argument for males to 
be offered a funded HPV vaccination to help achieve both personal gains against HPV and 
towards community focused immunity for both females and males. 
5.6 CONCLUSION 
Three of the studies focused on the cost of vaccination for males and this makes it hard to 
determine that the perceived high cost of providing a female and male vaccination programme 
is a strong enough argument against doing so, given that there are clear health benefits for 
males obtained from HPV vaccination. It could be considered unethical to offer a funded 
vaccination on the basis of sex alone when clear links have established the role of HPV in 
male cancers and genital warts. On the flip side of this it could be offered that it is unethical to 
spend considerable amount of money on HPV vaccination for males when a large amount of 
variables are unproven, given the cmTent price is deemed not cost effective. 
Through the last decade, there is much literature to prove the effectiveness of HPV for 
females and males, making the non-vaccination of males very controversial. An argument for 
the vaccination of males could lie in the statistics of HPV related disease treatments that is 
used on the male demographic including those of cancer. As the intensive treatment of HPV 
related diseases is known to be very costly even if for one individual alone, it could be argued 
that it would be cheaper to vaccinate against HPV than to try and later cure an HPV caused 
disease. In other words, prevention is better than cure. 
Despite the equivocal results the reviewer recommends that a funded vaccine for HPV should 
be universally available within New Zealand. The literature review itself has presented that 
HPV vaccine can help reduce the incidence of HPV related diseases, however possibly not 
with cost effectiveness. 
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Often health care is overshadowed by financial constraints and it appears that although HPV 
vaccine for females is well justified and funded, it may be some time before male vaccination 
is available in a funded fonn due to financial restrictions or restrictions on many variables that 
are at present unproven such as prevention of cancers or duration of efficacy. 
In concluding, it is clear that HPV affects males and females, concluding that HPV 
vaccination should be made available for males in a funded form as it has been for females .. 
Several disadvantages were highlighted throughout the literature review with the main theme 
being cost effectiveness. From a Ministry of Health perspective, cost effectiveness is a clear 
disadvantage, however whether this is a rationale for not funding males for an HPV vaccine 
when the risks of contracting such a destructive disease are so high, is hard to evaluate. 
It could be a considered view that it is biased and unethical that a funded HPV vaccine 
programme not be initiated to include males within the New Zealand setting given that a 
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